Gastrointestinal Stromal Tumor
Conditions
Keywords
gastrointestinal stromal tumor, GIST, neoadjuvant, imatinib
Brief summary
Gastrointestinal stromal tumors (GISTs) are a form of sarcoma and the most common sarcoma tumors of the gastrointestinal tract. The limited clinical experience suggests that GIST patients may benefit from neo-adjuvant therapy from primary GIST. This is a prospective, multicenter, open, observational study in evaluation of safety and efficacy of imatinib compared with that of historical data for locally unresectable advanced GIST without metastasis. The study will include an up to 28-day screening period, followed by receiving imatinib mesylate (400 mg/day) for at least 6-12 months and followed up for 3 years after surgery.
Detailed description
Primary Objective * To observe the safety of imatinib compared with that of historical data for locally unresectable advanced GIST without metastasis. Secondary Objective * Progression-free survival (PFS) in resected patients during follow up * R0 resection rate * objective response rate, tumor shrinkage rate * Correlation of mutation status with response * Correlation of PK with response * Surgical morbidity and mortality and safety follow up * Quality of life * Overall survival (OS)
Interventions
None listed
Sponsors
Chang Gung Memorial Hospital
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Locally advanced unresectable GIST without metastasis at * EC junction requiring total gastrectomy, * Duodenum requiring Whipple operation; * Large GIST requiring multiviceral resection; * Rectum: requiring APR. * Histologically documentation with positive immunostaining for KIT (CD117) * Patient age ≥ 18 years old * ECOG performance status 0 or 1 * Patient must have the following post-operative laboratory values confirmed within 14 days prior to registration: * Creatinine ≤ 1.5 times the institution ULN (upper limit of normal) * WBC ≥ 3,000/mm3 * Platelets ≥ 100,000/mm3 * Total Bilirubin ≤ 1.5 times the institution ULN. NOTE: Patients with elevated bilirubin secondary to Gilbert's disease are eligible to participate in the study. * AST ≤ 2.5 times the institution ULN * ALT ≤ 2.5 times the institution ULN * Female of childbearing potential must have negative serum pregnancy test. -- -NOTE: Post-menopausal women must be amenorrheic for at least 12 months to be deemed not of reproductive potential. * Patient is willing to sign informed consent.
Exclusion criteria
* Patient has received post-operative chemotherapy. * Patient has received post-operative radiation therapy. * Patient has received post-operative investigational treatment. * Patient has received prior therapy with imatinib, or any other molecular targeted or biological therapy. * Patient has had an active infection requiring antibiotics within 14 days prior to registration. * any prior malignancies for at least 5 years with potential evidence of recurrence (except for effectively treated basal cell or squamous carcinoma of the skin, carcinoma in-situ of the cervix that has been effectively treated by surgery alone, or lobular carcinoma in-situ of the ipsilateral or contralateral breast treated by surgery alone). * Patient is deemed by their treating physician to be at risk for recurrence from prior malignancies.New York Heart Association Class 3 or 4 cardiac diseases. * Patient is taking full dose warfarin. NOTE: The use of mini-dose warfarin (1 mg orally per day) for prevention of central line-associated deep venous thrombosis is permitted. * Presence of severe and/or uncontrolled concurrent medical disease (e.g., uncontrolled diabetes, uncontrolled chronic renal disease, uncontrolled liver disease, including chronic viral hepatitis judged at risk of reactivation, uncontrolled active infection, such as HIV infection, etc.). * Patient, if female and breastfeeding. NOTE: It is not known whether imatinib or its metabolites are excreted in human milk.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| progression free survival | five years | Evidence of measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines with CT scan. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate, tumor shrinkage rate | three years | all the participants |
| R0 resection rate | three years | all the participants |
| Correlation of PK with response | three years | check PK (trough level of imatinib)of all the participants at first month and every three months later to correlate with the response and check PK (peak level of imatinib) of all the participants who had adverse events |
| Surgical morbidity and mortality and safety follow up | five years | surgical morbidity: morbidity related to surgical procedure surgical mortality: mortality related to surgical procedure safety: adverse events related imatinib according to NIH toxicity evaluation criteria |
| Overall survival (OS) | five years | Overall survival (OS) will be measured from after administration of imatinib mesylate and death as the end point of the study, whatever the cause. Alive patients will be censored at the date of last follow-up. Causes of death will be recorded. |
Countries
Taiwan
Outcome results
None listed